NRXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
NRX Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$2.63+0.03 (+1.15%)
Close on Oct 19, 2026
- Market cap
- $99.02M
- P/E (TTM)
- –
- Dividend yield
- –
NRX Pharmaceuticals, Inc. revenue by segment
By business segment
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 |
|---|---|---|---|---|
| Dura Segment [Member] | $98.00K | $84.00K | -$102.00K | $15.00K |
| NRx Segment [Member] | -$6.60M | -$4.83M | -$4.52M | -$4.04M |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | % of revenue |
|---|---|---|---|---|---|
| Therapy [Member] | $871.00K | $760.00K | $702.00K | $152.00K | 79.1% |
| Procedures [Member] | $230.00K | $308.00K | $281.00K | $90.00K | 20.9% |
By region
From the segment and revenue-disaggregation notes of NRX Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.